Ivermectin resistance in Onchocerca volvulus: toward a genetic basis
- PMID: 17989789
- PMCID: PMC2041823
- DOI: 10.1371/journal.pntd.0000076
Ivermectin resistance in Onchocerca volvulus: toward a genetic basis
Conflict of interest statement
SL has received research grants for the development of anti-Onchocerca vaccines and macrofilaricides. JPM is a share-holder and employee of Divergence, Inc., a company that works on parasite control in plants, animals, and humans.
Figures
Comment on
-
Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment.PLoS Negl Trop Dis. 2007 Aug 30;1(1):e72. doi: 10.1371/journal.pntd.0000072. PLoS Negl Trop Dis. 2007. PMID: 17989786 Free PMC article.
References
-
- Richards FO, Jr, Boatin B, Sauerbrey M, Seketeli A. Control of onchocerciasis today: status and challenges. Trends Parasitol. 2001;17:558–563. - PubMed
-
- African Programme for Onchocerciasis Control. Final communiqué of the 11th session of the Joint Action Forum (JAF) of APOC, Paris, France, 6–9 December 2005. 2005 Available: http://www.apoc.bf/en/download.htm. Accessed 3 August 2007.
-
- Peters DH, Phillips T. Mectizan Donation Program: Evaluation of a public–private partnership. Trop Med Int Health. 2004;9:A4–A15. - PubMed
-
- Ejere H, Schwartz E, Wormald R. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev. 2001:CD002219. - PubMed
-
- Tielsch JM, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health. 2004;9:A45–A56. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
